Blunt Business zeroes in on major developments unfolding on the congressional front. It highlights how impending federal rescheduling could significantly alter medical cannabis policies within the Veterans Administration, potentially expanding access for military veterans by allowing VA doctors to discuss and document use, as well as refer patients to state-approved programs.

Additionally, we break down the bipartisan BUILD Act (Building Unrivaled Infrastructure and Long-Term Development Act), a piece of transportation legislation moving toward a House floor vote. The bill directives mandate federal agencies to invest $110 million to research poly-substance impairment and establish standardized, evidence-based driving limits, addressing the long-standing scientific flaws and regional inconsistencies currently plaguing roadside testing.

This week on Blunt Business, we’re diving into two massive legal shifts reshaping cannabis markets on opposite sides of the country. First, we break down Georgia’s major policy overhaul as Governor Brian Kemp signs the "Putting Georgia's Patients First Act."From expanding the list of qualifying conditions to include lupus, to lifting strict "end-stage" limitations and allowing adult vaping and edibles, the Peach State is dramatically widening medical access.

Then, we pivot to Washington, D.C., where a high-stakes federal lawsuit challenging the District's cannabis licensing and enforcement system was suddenly dropped. We’ll analyze why the Alliance for Recreational Cannabis Entities voluntarily dismissed their case, how a recent federal appeals court ruling regarding the Dormant Commerce Clause triggered the move, and what this unresolved constitutional battle means for local market protections across the United States.

As the federal government moves toward rescheduling marijuana, the cannabis industry is eyeing a massive financial shift: the potential for $15 billion in retroactive tax relief from Section 280E. While the transition to Schedule 3 offers a path to future profitability, businesses must act immediately to file protective claims before statutes of limitation expire.

This economic evolution coincides with a significant demographic pivot, as older adults become the fastest-growing consumer group, frequently choosing edibles for pain and sleep management over pharmaceuticals.

However, the move toward higher-potency THC products is a double-edged sword, with new studies linking high-strength medicinal cannabis to increased risks of anxiety and psychiatric side effects, underscoring the need for careful regulation and informed medical guidance.

The potential move to Schedule III presents a massive financial opportunity for "Sin City," yet current local friction threatens to stall that momentum. As the federal government nears reclassification, the industry is at a crossroads between record-breaking growth and a cooling tourist market.

While the city is built on "cashing in," Las Vegas could be losing tourists due to a recent crackdown on public consumption and strict enforcement. For the city to fully capitalize on the "Green Rush," it must reconcile its status as a global playground with the reality of a regulated cannabis market. If tourists feel penalized for legal use, they may take their gambling and entertainment dollars elsewhere.

The shift to Schedule III is the "jackpot" many operators have been waiting for, primarily due to the removal of the 280E tax penalty. This change would allow businesses to finally treat cannabis like a standard industry, potentially injecting millions back into the local economy.

This episode of Blunt Business explores a significant shift in federal drug policy following a new executive order aimed at accelerating research into psychedelics like LSD, psilocybin, and ibogaine for treating mental health disorders.

The newly signed executive order to direct the FDA to fast-track these compounds through new "National Priority" vouchers.

Beyond psychedelics, the host discusses the impact of GLP-1 weight-loss drugs (like Ozempic) on the cannabis market, noting that dispensaries are seeing a shift in consumer preference toward lower-dose products to mitigate "the munchies."

As the legal landscape evolves, the traditional 4/20 retail boom is showing signs of cooling, with some markets seeing higher sales during the surrounding week than on the holiday itself due to aggressive discounting and operational strain.

This shift toward a more mature market coincides with significant legal and scientific developments: the District of Columbia is currently citing federal appellate rulings to defend its licensing framework against constitutional challenges, while recent research highlights that THC can impair memory to the point of creating false recollections.

Furthermore, economists warn that while legalization has spurred a wave of innovation, much of it is focused on commercial expansion rather than genuine public health benefits.

The cannabis landscape in Massachusetts and the broader U.S. market is undergoing a significant correction as regulators and major corporations grapple with the industry's economic realities.

In a move toward increased oversight and efficiency, a state legislative committee has passed a plan to downsize and restructure the Cannabis Control Commission, signaling a major pivot in how the state manages its legal market.

This push for reform arrives at a precarious time for the industry, underscored by the news that a major marijuana Multi-State Operator (MSO) has filed for U.S. bankruptcy protections.

These developments highlight a dual trend of tightening governance and financial instability among the sector's largest players, suggesting that the "green rush" is entering a more sober, disciplined era of consolidation and reform.

In this episode of The Blunt Business, the discussion dives deep into the complex landscape of the New York cannabis market as it hits its five-year legalization anniversary.

While Governor Kathy Hochul lauds the state’s achievement of $3.3 billion in total sales and the opening of its 600th licensed dispensary, the program highlights a more turbulent reality behind the numbers. Industry experts and operators share insights on the "whack-a-mole" battle against a rampant illicit market, the "red tape" and bureaucracy stifling small businesses, and the ongoing struggle to fulfill social equity promises amidst predatory loans and licensing bottlenecks.

From critical BBC reports to exclusive interviews with OCM leadership, this summary explores whether New York's green revolution is truly flying high or simply struggling to find its footing.